MayTech Global Investments LLC Buys 188 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

MayTech Global Investments LLC lifted its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 0.4% during the 4th quarter, Holdings Channel reports. The firm owned 50,575 shares of the medical equipment provider’s stock after acquiring an additional 188 shares during the period. Intuitive Surgical makes up 3.5% of MayTech Global Investments LLC’s holdings, making the stock its 15th biggest holding. MayTech Global Investments LLC’s holdings in Intuitive Surgical were worth $17,062,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Provence Wealth Management Group bought a new position in shares of Intuitive Surgical in the 4th quarter worth $276,000. Portside Wealth Group LLC lifted its holdings in Intuitive Surgical by 8.2% during the fourth quarter. Portside Wealth Group LLC now owns 816 shares of the medical equipment provider’s stock worth $275,000 after acquiring an additional 62 shares in the last quarter. Sequoia Financial Advisors LLC lifted its holdings in Intuitive Surgical by 58.0% during the fourth quarter. Sequoia Financial Advisors LLC now owns 8,315 shares of the medical equipment provider’s stock worth $2,805,000 after acquiring an additional 3,054 shares in the last quarter. HCR Wealth Advisors lifted its holdings in Intuitive Surgical by 26.3% during the fourth quarter. HCR Wealth Advisors now owns 1,042 shares of the medical equipment provider’s stock worth $352,000 after acquiring an additional 217 shares in the last quarter. Finally, Kades & Cheifetz LLC bought a new position in Intuitive Surgical during the fourth quarter worth about $230,000. 83.64% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Intuitive Surgical news, VP Fredrik Widman sold 5,041 shares of the business’s stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $397.07, for a total transaction of $2,001,629.87. Following the transaction, the vice president now owns 110 shares of the company’s stock, valued at $43,677.70. The sale was disclosed in a document filed with the SEC, which is available through this link. In other Intuitive Surgical news, VP Fredrik Widman sold 5,041 shares of the business’s stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $397.07, for a total transaction of $2,001,629.87. Following the transaction, the vice president now owns 110 shares of the company’s stock, valued at $43,677.70. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Mark Brosius sold 175 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $389.16, for a total value of $68,103.00. Following the sale, the senior vice president now owns 883 shares of the company’s stock, valued at approximately $343,628.28. The disclosure for this sale can be found here. Insiders have sold a total of 21,597 shares of company stock valued at $8,339,157 over the last 90 days. 0.80% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. StockNews.com lowered Intuitive Surgical from a “buy” rating to a “hold” rating in a report on Thursday, February 29th. The Goldman Sachs Group assumed coverage on Intuitive Surgical in a report on Thursday, May 30th. They set a “buy” rating and a $500.00 target price on the stock. Stifel Nicolaus lifted their target price on Intuitive Surgical from $420.00 to $430.00 and gave the stock a “buy” rating in a report on Monday, April 8th. BTIG Research lifted their target price on Intuitive Surgical from $412.00 to $421.00 and gave the stock a “buy” rating in a report on Friday, April 19th. Finally, Robert W. Baird reduced their target price on Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating on the stock in a report on Friday, April 19th. Five investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $403.67.

Intuitive Surgical Stock Up 2.2 %

Shares of NASDAQ:ISRG traded up $9.32 during midday trading on Wednesday, reaching $428.10. The company had a trading volume of 1,251,474 shares, compared to its average volume of 1,511,173. The business’s 50 day moving average price is $391.07 and its 200 day moving average price is $372.87. The stock has a market cap of $151.85 billion, a PE ratio of 77.27, a P/E/G ratio of 5.40 and a beta of 1.39. Intuitive Surgical, Inc. has a 1-year low of $254.85 and a 1-year high of $428.86.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.10. The firm had revenue of $1.89 billion for the quarter, compared to the consensus estimate of $1.87 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The business’s revenue was up 11.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.00 earnings per share. On average, research analysts expect that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current fiscal year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.